Abstract OT2-27-02: A prospective phase II study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally advanced or metastatic breast cancer
Authors: Xiaojia Wang, Jian Huang
Published: 2022-03-08
DOI:
10.1158/1538-7445.sabcs21-ot2-27-02
Source:
Full article
Abstract
Abstract